Scaling Next-Gen MSC Therapies Without Scaling Risk

Mesenchymal stromal cell (MSC) therapies are entering a pivotal stage of development. As more programs move toward late-stage clinical trials and commercialization, developers must produce enough high-quality cells to meet growing demand while maintaining potency, consistency, and manufacturability. 

Cell & Gene's Chief Editor, Erin Harris, spoke with Miguel Forte, MD, Ph.D., CEO of Kiji Therapeutics, Michael Schuster, Co-Founder and Head of Business Development of Mesoblast, and Edward Ahn, Ph.D., CEO of MEDIPOST. Together, these experts coered how companies can scale MSC production without compromising the biological properties that drive therapeutic efficacy.